首页> Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research> Linking Reimbursement to Patient Benefits for Advanced Therapy Medicinal Products and Other High-Cost Innovations: Policy Recommendations for Outcomes-Based Agreements in Europe.

Linking Reimbursement to Patient Benefits for Advanced Therapy Medicinal Products and Other High-Cost Innovations: Policy Recommendations for Outcomes-Based Agreements in Europe.

导出原文传递

翻译打印收藏纠错

第一作者： Tuba Saygın,Avşar

第一单位： Science Policy and Research Program, National Institute for Health and Care Excellence (NICE), United Kingdom.

作者： Tuba Saygın,Avşar ^[1] ; Jamie,Elvidge ^[2] ; Claire,Hawksworth ^[1] ; Juliet,Kenny ^[1] ; Bertalan,Németh ^[3] ; Marcelien,Callenbach ^[4] ; Johanna,Ringkvist ^[5] ; Dalia,Dawoud ^[1]

作者单位： Science Policy and Research Program, National Institute for Health and Care Excellence (NICE), United Kingdom. ^[1] Science Policy and Research Program, National Institute for Health and Care Excellence (NICE), United Kingdom. Electronic address: jamie.elvidge@nice.org.uk. ^[2] Syreon Research Institute, Budapest, Hungary. ^[3] Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands. ^[4] The Dental and Pharmaceutical Benefits Agency (TLV), Sweden. ^[5]

关键词 advanced therapy medicinal products health technology assessment managed entry access outcome-based agreements policy

医学主题词人类(Humans);欧洲(Europe);技术评估, 生物医学(Technology Assessment, Biomedical);卫生政策(Health Policy);偿还途径(Reimbursement Mechanisms);费用效益分析(Cost-Benefit Analysis);保险, 健康, 补偿(Insurance, Health, Reimbursement)

DOI 10.1016/j.jval.2024.07.007

PMID 39094693

发布时间 2025-03-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交